Physician
Henry Heywood Memorial Hospital
Henry Heywood Memorial Hospital was paid $54.50M by Medicaid between Jan 2018 and Dec 2024, across 445 billing codes. Its largest line is 99284, emergency room visit (serious) — 7.9% of everything it billed.
33Billing provider infoHENRY HEYWOOD MEMORIAL HOSPITAL
GARDNER, MA 01440
GARDNER, MA 01440
33aNPI1205823879assigned 09/29/2005
33bProvider typeGeriatric Psychiatry Physician
28Total paid$54.50M
24GClaims1,506,494
24DCodes billed445
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Geriatric Psychiatry Physician providers in Massachusetts
Rank by total paid#1 of 6
Median peer was paid$6K
This provider vs. median8,821×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 216,603 | $6.99M | |
| 2019 | 230,624 | $7.45M | |
| 2020 | 190,908 | $6.24M | |
| 2021 | 221,120 | $7.77M | |
| 2022 | 250,902 | $9.04M | |
| 2023 | 217,808 | $9.03M | |
| 2024incomplete | 178,529 | $7.98M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.9% | 40,861 | 37,701 | $4.33M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.9% | 37,960 | 34,211 | $4.29M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.2% | 31,652 | 27,802 | $3.94M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.4% | 22,880 | 20,496 | $3.50M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 5.2% | 18,959 | 15,812 | $2.85M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.2% | 20,874 | 19,032 | $2.84M |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.5% | 7,561 | 6,603 | $2.43M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.5% | 33,789 | 27,242 | $1.90M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.2% | 33,940 | 9,353 | $1.73M |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 3.2% | 9,958 | 9,283 | $1.72M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.1% | 44,169 | 35,646 | $1.14M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.9% | 1,742 | 1,537 | $1.04M |
433 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 7,334 | $950K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.6% | 6,582 | $860K |
| 99204 | Doctor's office visit, new patient (more involved) | 1.4% | 5,055 | $784K |
| 99203 | Doctor's office visit, new patient (routine) | 1.4% | 4,306 | $750K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 5,015 | $714K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.2% | 4,934 | $649K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 6,757 | $639K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.1% | 4,408 | $620K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 20,821 | $613K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.1% | 698 | $602K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.0% | 16,444 | $556K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 5,223 | $529K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 4,137 | $501K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 10,057 | $489K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 3,857 | $468K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 6,116 | $428K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 26,372 | $424K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,578 | $369K |
| G0378 | Hospital observation service, per hour | <1% | 7,297 | $368K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 2,759 | $365K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,995 | $321K |
| 20610 | <1% | 2,007 | $290K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,675 | $283K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,044 | $253K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 69,956 | $250K |
| 97161 | <1% | 3,706 | $247K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,787 | $242K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,895 | $229K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 2,084 | $211K |
| 76830 | Ultrasound, transvaginal | <1% | 2,253 | $211K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 8,929 | $196K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,928 | $193K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,726 | $191K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,587 | $181K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 338 | $162K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,272 | $162K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 9,511 | $150K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 995 | $149K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 558 | $137K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 18,518 | $134K |
| 80053 | Comprehensive metabolic panel | <1% | 60,768 | $130K |
| ATP14 | <1% | 20,215 | $129K | |
| 92551 | <1% | 1,530 | $127K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 969 | $127K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,450 | $126K |
| 97803 | <1% | 2,245 | $126K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 110 | $123K |
| 80050 | General health panel | <1% | 8,504 | $120K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 409 | $119K |
| 62323 | <1% | 358 | $110K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 679 | $102K |
| 97162 | <1% | 1,826 | $102K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 5,143 | $96K |
| 96127 | <1% | 6,067 | $94K | |
| 93017 | <1% | 1,218 | $91K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 19,484 | $88K |
| 99218 | <1% | 3,854 | $86K | |
| 71250 | <1% | 1,584 | $86K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 560 | $86K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 4,671 | $86K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,953 | $84K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,041 | $83K |
| 80061 | Lipid panel | <1% | 27,050 | $83K |
| 87070 | <1% | 13,133 | $80K | |
| 76642 | <1% | 1,025 | $80K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14,777 | $78K |
| 90839 | <1% | 1,315 | $73K | |
| 93971 | <1% | 525 | $71K | |
| 82607 | <1% | 9,182 | $67K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,003 | $67K |
| 83880 | <1% | 5,906 | $66K | |
| 73630 | <1% | 3,627 | $62K | |
| 84702 | <1% | 5,076 | $58K | |
| 84484 | <1% | 11,227 | $57K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,138 | $57K |
| 99173 | <1% | 1,932 | $56K | |
| 87634 | <1% | 1,424 | $56K | |
| S9485 | Crisis intervention mental health services, per diem | <1% | 226 | $56K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,105 | $56K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 724 | $55K |
| 73610 | <1% | 3,083 | $54K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,929 | $53K |
| 73562 | <1% | 2,641 | $53K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 15,440 | $53K |
| 82746 | <1% | 6,676 | $51K | |
| 83690 | <1% | 13,187 | $51K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,398 | $50K |
| 77065 | Tomosynthesis, mammo | <1% | 732 | $50K |
| 87077 | <1% | 10,740 | $49K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,123 | $48K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,065 | $47K |
| 86803 | <1% | 5,046 | $47K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 313 | $46K |
| 99223 | Prolong inpt eval add15 m | <1% | 584 | $46K |
| 87186 | <1% | 9,255 | $46K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,662 | $46K |
| 73030 | <1% | 2,703 | $45K | |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 154 | $45K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,318 | $45K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 311 | $45K |
| 59025 | Fetal non-stress test | <1% | 180 | $44K |
| 84466 | <1% | 6,780 | $43K | |
| 43235 | <1% | 190 | $43K | |
| 87088 | <1% | 8,641 | $43K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 6,620 | $43K |
| 87143 | <1% | 6,660 | $42K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,495 | $42K |
| 82728 | <1% | 5,998 | $41K | |
| 73110 | <1% | 2,438 | $40K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,457 | $39K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,133 | $39K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,043 | $38K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 129 | $38K |
| 72100 | <1% | 1,342 | $38K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 238 | $38K |
| 73130 | <1% | 2,382 | $38K | |
| ATP08 | <1% | 8,968 | $35K | |
| 97597 | <1% | 762 | $34K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 24,113 | $33K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 722 | $33K |
| 90715 | <1% | 1,570 | $33K | |
| 85027 | <1% | 11,361 | $33K | |
| 76801 | <1% | 284 | $32K | |
| 83735 | <1% | 10,412 | $32K | |
| 83655 | <1% | 2,879 | $31K | |
| ATP17 | <1% | 7,164 | $31K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,768 | $29K |
| 95886 | <1% | 281 | $28K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,886 | $28K |
| 84439 | <1% | 5,856 | $28K | |
| 71271 | <1% | 731 | $27K | |
| 64635 | <1% | 60 | $27K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 20,465 | $27K |
| 84153 | <1% | 3,230 | $26K | |
| 81001 | <1% | 16,653 | $25K | |
| 97164 | <1% | 438 | $24K | |
| 76000 | <1% | 670 | $24K | |
| 73564 | <1% | 1,647 | $23K | |
| 83540 | <1% | 6,999 | $23K | |
| 73502 | <1% | 1,565 | $23K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,483 | $22K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,923 | $21K |
| ATP03 | <1% | 5,535 | $21K | |
| 81002 | <1% | 9,373 | $21K | |
| ATP15 | <1% | 3,228 | $21K | |
| 99221 | <1% | 784 | $21K | |
| 81025 | <1% | 4,011 | $20K | |
| 76536 | <1% | 206 | $19K | |
| 76775 | <1% | 243 | $19K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,828 | $18K |
| 92557 | <1% | 285 | $18K | |
| 86618 | <1% | 1,270 | $18K | |
| 90381 | <1% | 14 | $17K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,667 | $17K |
| 76770 | <1% | 114 | $17K | |
| 85610 | <1% | 13,624 | $17K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,468 | $17K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,476 | $16K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 174 | $15K |
| 00731 | <1% | 405 | $15K | |
| 86850 | <1% | 1,906 | $14K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 26 | $14K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 362 | $14K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 575 | $14K |
| 86140 | <1% | 4,957 | $14K | |
| 81003 | <1% | 12,283 | $14K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 207 | $14K |
| 87040 | <1% | 1,988 | $14K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 103 | $14K |
| 82043 | <1% | 5,882 | $13K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 551 | $13K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 333 | $13K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,539 | $13K |
| 86317 | <1% | 978 | $13K | |
| 77080 | <1% | 316 | $13K | |
| 82570 | <1% | 5,604 | $12K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,091 | $12K |
| 99220 | <1% | 89 | $12K | |
| 12001 | <1% | 97 | $12K | |
| 85379 | <1% | 2,195 | $12K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 604 | $11K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 124 | $11K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,362 | $11K |
| 87340 | <1% | 1,411 | $11K | |
| 90677 | <1% | 156 | $10K | |
| 64636 | <1% | 89 | $10K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 2,092 | $10K |
| 82948 | <1% | 4,945 | $9K | |
| 99205 | Prolong outpt/office vis | <1% | 60 | $8K |
| 95831 | <1% | 1,173 | $8K | |
| 93296 | <1% | 432 | $8K | |
| 83605 | <1% | 1,646 | $8K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 140 | $8K |
| 74018 | <1% | 348 | $8K | |
| 85018 | <1% | 4,646 | $8K | |
| 20552 | <1% | 64 | $8K | |
| 92567 | <1% | 542 | $7K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 125 | $7K |
| 94726 | <1% | 255 | $7K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,043 | $7K |
| 86038 | <1% | 928 | $7K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 457 | $7K |
| 36415 | Collection of venous blood by venipuncture | <1% | 66,157 | $7K |
| 90837 | Psychotherapy session, about an hour | <1% | 255 | $7K |
| 86592 | <1% | 1,375 | $6K | |
| 84146 | <1% | 557 | $6K | |
| 90688 | <1% | 448 | $6K | |
| 97750 | <1% | 144 | $6K | |
| 85730 | <1% | 2,096 | $6K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 96 | $5K |
| 94729 | <1% | 240 | $5K | |
| 83516 | <1% | 566 | $5K | |
| 94664 | <1% | 1,136 | $5K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 132 | $5K |
| 93299 | <1% | 347 | $5K | |
| 86900 | <1% | 2,230 | $5K | |
| 87807 | <1% | 516 | $5K | |
| 97802 | <1% | 74 | $5K | |
| 90686 | <1% | 1,941 | $5K | |
| 96160 | <1% | 692 | $5K | |
| 77066 | Tomosynthesis, mammo | <1% | 64 | $5K |
| 94060 | <1% | 42 | $5K | |
| 97116 | <1% | 258 | $4K | |
| 85651 | <1% | 2,206 | $4K | |
| 86901 | <1% | 2,190 | $4K | |
| V5266 | Battery for use in hearing device | <1% | 247 | $4K |
| 85652 | <1% | 2,964 | $4K | |
| 95911 | <1% | 13 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,935 | $4K |
| 83970 | <1% | 223 | $4K | |
| 92588 | <1% | 13 | $4K | |
| ATP13 | <1% | 655 | $4K | |
| J3300 | Injection, triamcinolone acetonide, preservative free, 1 mg | <1% | 45 | $4K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 72 | $4K |
| 93975 | <1% | 27 | $3K | |
| 88342 | <1% | 1,549 | $3K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 470 | $3K |
| 0072A | <1% | 72 | $3K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 13 | $3K |
| 85014 | <1% | 2,383 | $3K | |
| 00812 | <1% | 53 | $3K | |
| 77061 | <1% | 68 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 46 | $3K |
| 88304 | <1% | 1,138 | $3K | |
| 11043 | <1% | 19 | $3K | |
| 82784 | <1% | 444 | $3K | |
| 87653 | <1% | 95 | $3K | |
| 72141 | <1% | 32 | $3K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 53 | $3K |
| 84460 | <1% | 4,149 | $3K | |
| 11721 | <1% | 140 | $2K | |
| 96367 | <1% | 88 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,336 | $2K |
| ATP11 | <1% | 549 | $2K | |
| 80164 | <1% | 554 | $2K | |
| 80076 | <1% | 2,400 | $2K | |
| 74183 | <1% | 43 | $2K | |
| 73080 | <1% | 172 | $2K | |
| 73140 | <1% | 114 | $2K | |
| 90461 | <1% | 3,031 | $2K | |
| ATP07 | <1% | 465 | $2K | |
| 94761 | <1% | 3,832 | $2K | |
| 0071A | <1% | 48 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,794 | $2K |
| 92587 | <1% | 18 | $2K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 12 | $2K |
| 86762 | <1% | 170 | $2K | |
| 82248 | <1% | 3,850 | $2K | |
| 82150 | <1% | 417 | $2K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 76 | $2K |
| 84450 | <1% | 2,961 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,904 | $2K |
| 99406 | <1% | 119 | $2K | |
| 85007 | <1% | 1,482 | $2K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 37 | $1K |
| 88141 | <1% | 118 | $1K | |
| 97166 | <1% | 15 | $1K | |
| 90670 | <1% | 1,076 | $1K | |
| 82805 | <1% | 45 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 30 | $1K |
| Q3014 | Telehealth originating site facility fee | <1% | 322 | $1K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 569 | $1K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 12 | $1K |
| 85049 | <1% | 578 | $1K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 41 | $1K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,362 | $974.72 |
| 93016 | <1% | 65 | $956.69 | |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | <1% | 5,381 | $912.90 |
| 83721 | <1% | 311 | $884.94 | |
| 86706 | <1% | 132 | $880.63 | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 214 | $858.87 |
| 87081 | <1% | 170 | $814.37 | |
| 82950 | <1% | 169 | $706.70 | |
| 83525 | <1% | 92 | $695.52 | |
| 0073A | <1% | 15 | $688.05 | |
| 84402 | <1% | 44 | $673.80 | |
| 51798 | <1% | 735 | $672.97 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,437 | $669.82 |
| 93018 | <1% | 65 | $637.07 | |
| 93041 | <1% | 6,064 | $636.44 | |
| 94010 | <1% | 12 | $622.21 | |
| 72050 | <1% | 25 | $614.80 | |
| 84425 | <1% | 39 | $597.90 | |
| 77062 | <1% | 12 | $597.19 | |
| 72040 | <1% | 43 | $569.14 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 867 | $561.79 |
| 86431 | <1% | 183 | $554.36 | |
| G0008 | Administration of influenza virus vaccine | <1% | 423 | $543.01 |
| 90656 | <1% | 56 | $536.51 | |
| 94760 | <1% | 10,372 | $534.23 | |
| 83001 | <1% | 39 | $531.92 | |
| 74019 | <1% | 50 | $529.27 | |
| 90662 | <1% | 114 | $514.39 | |
| 93880 | <1% | 13 | $497.68 | |
| 84550 | <1% | 761 | $461.25 | |
| 82550 | <1% | 838 | $437.97 | |
| 86787 | <1% | 46 | $408.96 | |
| 84100 | <1% | 1,775 | $391.70 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 766 | $390.04 |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 27 | $382.17 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,749 | $368.62 |
| 87046 | <1% | 66 | $362.72 | |
| 99217 | <1% | 12 | $352.02 | |
| 82565 | <1% | 895 | $297.91 | |
| ATP10 | <1% | 115 | $295.68 | |
| 86430 | <1% | 68 | $269.20 | |
| 70486 | <1% | 12 | $246.80 | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 96 | $243.39 |
| 85045 | <1% | 134 | $235.84 | |
| 82803 | <1% | 30 | $235.26 | |
| ATP18 | <1% | 71 | $230.97 | |
| ATP09 | <1% | 106 | $219.58 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 1,287 | $213.03 |
| 84311 | <1% | 207 | $200.10 | |
| ATP02 | <1% | 61 | $187.95 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 409 | $164.06 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 61 | $152.28 |
| 87210 | <1% | 51 | $137.60 | |
| 87075 | <1% | 50 | $135.20 | |
| 86666 | <1% | 14 | $120.05 | |
| ATP16 | <1% | 17 | $108.90 | |
| 83986 | <1% | 214 | $103.04 | |
| 83789 | <1% | 38 | $93.10 | |
| 80178 | <1% | 53 | $88.16 | |
| 86704 | <1% | 12 | $87.92 | |
| 96376 | <1% | 922 | $86.02 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 5,176 | $77.71 |
| ATP04 | <1% | 14 | $72.40 | |
| 84134 | <1% | 14 | $61.96 | |
| 84436 | <1% | 14 | $56.64 | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 1,103 | $50.40 |
| J1815 | Injection, insulin, per 5 units | <1% | 55 | $47.30 |
| 83615 | <1% | 171 | $43.41 | |
| 88302 | <1% | 12 | $41.27 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 371 | $27.02 |
| 84520 | <1% | 135 | $20.71 | |
| 82947 | <1% | 38 | $20.25 | |
| 81000 | <1% | 13 | $19.62 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 38 | $16.78 |
| 99188 | <1% | 306 | $13.92 | |
| 88112 | <1% | 15 | $11.88 | |
| 84132 | <1% | 15 | $9.46 | |
| 85008 | <1% | 68 | $3.03 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 1,400 | $2.48 |
| 95851 | <1% | 261 | $1.72 | |
| G9744 | Patient not eligible due to active diagnosis of hypertension | <1% | 294 | $0.02 |
| 80320 | 0% | 1,025 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 302 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 569 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 100 | $0.00 |
| 90716 | 0% | 52 | $0.00 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 356 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 106 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 217 | $0.00 |
| 90723 | 0% | 687 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 377 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 79 | $0.00 |
| 80358 | 0% | 110 | $0.00 | |
| 87493 | 0% | 53 | $0.00 | |
| 80329 | 0% | 197 | $0.00 | |
| G8952 | Elevated or hypertensive blood pressure reading documented, indicated follow-up not documented, reason not given | 0% | 167 | $0.00 |
| 80359 | 0% | 110 | $0.00 | |
| G8950 | Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented | 0% | 26 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 65 | $0.00 |
| 91307 | 0% | 163 | $0.00 | |
| 80324 | 0% | 112 | $0.00 | |
| 72170 | 0% | 13 | $0.00 | |
| 80353 | 0% | 110 | $0.00 | |
| 90651 | 0% | 14 | $0.00 | |
| 90697 | 0% | 52 | $0.00 | |
| 90696 | 0% | 12 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 12 | $0.00 |
| 88311 | 0% | 13 | $0.00 | |
| S3005 | Performance measurement, evaluation of patient self assessment, depression | 0% | 609 | $0.00 |
| 90648 | 0% | 1,116 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 16 | $0.00 |
| 90671 | 0% | 46 | $0.00 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 533 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 68 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 99 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 289 | $0.00 |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | 0% | 298 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 404 | $0.00 |
| 80179 | 0% | 99 | $0.00 | |
| 80365 | 0% | 110 | $0.00 | |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 153 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 441 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 33 | $0.00 |
| 90633 | 0% | 402 | $0.00 | |
| 99053 | 0% | 102 | $0.00 | |
| 73590 | 0% | 15 | $0.00 | |
| 84145 | 0% | 95 | $0.00 | |
| 80143 | 0% | 126 | $0.00 | |
| 80354 | 0% | 110 | $0.00 | |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 26 | $0.00 |
| 90681 | 0% | 126 | $0.00 | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | 0% | 30 | $0.00 |
| 80348 | 0% | 149 | $0.00 | |
| 90658 | 0% | 28 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 63 | $0.00 |
| 90700 | 0% | 25 | $0.00 | |
| 80373 | 0% | 110 | $0.00 | |
| 90685 | 0% | 35 | $0.00 | |
| 51702 | 0% | 29 | $0.00 | |
| 80372 | 0% | 110 | $0.00 | |
| 80346 | 0% | 110 | $0.00 | |
| 90707 | 0% | 12 | $0.00 | |
| 82542 | 0% | 44 | $0.00 | |
| 90473 | 0% | 27 | $0.00 | |
| 90791 | Psychiatric diagnostic evaluation | 0% | 13 | $0.00 |
| 90710 | 0% | 24 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 18 | $0.00 |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSULLIVAN, THOMAS (CEO)
Parent organizationNORTH CENTRAL HEALTHCARE, INC
| Provider | Location | Paid |
|---|---|---|
| Athol Memorial Hospital Incorporated | Athol, MA | $30.77M |
| Heywood Medical Group INC. | Gardner, MA | $4.22M |
| Heywood Affiliated Medical Group INC. | Gardner, MA | $734K |
| Heywood Medical Group INC | Athol, MA | $436K |
| Athol Memorial Hospital Incorporated | Athol, MA | $162K |
| Athol Memorial Hospital Incorporated | Athol, MA | $52K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.